UBH Denton

ubhdenton.com

University Behavioral Health of Denton is a private freestanding psychiatric hospital specializing in mental health and chemical dependency care. Serving north Texas and surrounding areas since 2005, we provide a wide range of services and programs that offer evidence-based treatment proven to have positive outcomes for our patients. Our inpatient and day hospital, or outpatient, services offer supportive and compassionate care for children, adolescents, adults and mature adults through specialty programs that are tailored to meet the needs of our patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

news image

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

news image

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More

Medical

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

Frontage | January 02, 2024

news image

Frontage Laboratories, Inc. announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More

Industrial Impact

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

news image

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More
news image

Medical

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More
news image

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More
news image

Medical

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

Frontage | January 02, 2024

Frontage Laboratories, Inc. announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More
news image

Industrial Impact

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us